Attached files

file filename
EX-31.2 - CERTIFICATION - Sunshine Biopharma, Incsbfm_ex3102.htm
EX-31.1 - CERTIFICATION - Sunshine Biopharma, Incsbfm_ex3101.htm
10-Q - FORM 10-Q - Sunshine Biopharma, Incsbfm_i10q-20210630.htm

 

Exhibit 32

 

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with this quarterly report of Sunshine Biopharma, Inc. (the “Company”) on Form 10-Q for the six month period ended June 30, 2021, as filed with the Securities and Exchange Commission on August 9, 2021 (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

 

1.The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Dated: August 9, 2021

/s/ Dr. Steve N. Slilaty

Dr. Steve N. Slilaty, Chief Executive Officer

   
Dated: August 9, 2021

/s/ Camille Sebaaly

Camille Sebaaly, Chief Financial Officer